Breaking News Instant updates and real-time market news.

UMRX

Unum Therapeutics

$1.78

-0.01 (-0.56%)

07:33
08/13/19
08/13
07:33
08/13/19
07:33

Unum Therapeutics price target lowered to $13 from $20 at Wedbush

Wedbush analyst David Nierengarten lowered his price target for Unum Therapeutics to $13 from $20, while reiterating an Outperform rating on the shares. The analyst notes that the company provided a preliminary update from the Phase 1 ATTCK-20-03 trial of ACTR707 + rituximab combo in r/r B-cell non-Hodgkin lymphoma with data from Cohort 3, which had a complete response of 20% and an overall response rate of 80%. Although the analyst acknowledges that it was "encouraging" to see a higher response rate in Cohort 3, the slip in CR rate is "difficult to overlook," given a CR of 50% and 33% in Cohorts 1 and 2, respectively. Nonetheless, Nierengarten sees the data readouts in the second half of 2019 as opportunity to lend credibility to Unum Therapeutics' platform and provide upside to the company's valuation.

  • 09

    Sep

UMRX Unum Therapeutics
$1.78

-0.01 (-0.56%)

07/03/19
MSCO
07/03/19
NO CHANGE
Target $18
MSCO
Overweight
Clinical hold not a 'major event' for Unum Therapeutics, says Morgan Stanley
After Unum Therapeutics announced that the FDA has placed a clinical hold on the Phase 1 trial ATTCK-20-2 evaluating Unum's ACTR087 in combination with rituximab, Morgan Stanley analyst Matthew Harrison said he does not view this as a "major event" given that management had previously de-prioritized the program during its earnings call last November. Lead program ACTR707 has reported no DLTs or serious adverse events of CRS or neurotoxicity through the first three patient cohorts as of May 7, noted Harrison, who would argue that ACTR707 "clearly has a different safety profile" than ACTR087. He maintains an Overweight rating on Unum Therapeutics shares.
07/03/19
RHCO
07/03/19
NO CHANGE
Target $6
RHCO
Buy
Unum Therapeutics price target lowered to $6 from $10 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Unum Therapeutics to $6 after yesterday's FDA announcement of a clinical hold on its Phase 1 trial ATTCK-20-2 evaluating ACTR087 in combination with rituximab. The analyst is retaining a Buy rating on the stock however, stating that his discussions with the management indicated the program was already de-prioritized in November of 2018 "in favor of the '707 construct", and the hold should yield a limited read through to other programs.
07/03/19
COWN
07/03/19
NO CHANGE
COWN
Market Perform
Unum Therapeutics clinical hold not an issue, says Cowen
Cowen analyst Yaron Werber noted the FDA placed a clinical hold on ACTR087 adding to ongoing concerns about the potential of its platform given lackluster efficacy data. The analyst said the hold is not an issue as it was deprioritized and the prospects for the stock may lie in the BOXR platform. Werber maintained his Market Perform rating on Unum Therapeutics shares.
07/03/19
HCWC
07/03/19
NO CHANGE
Target $18
HCWC
Buy
Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright
Unum Therapeutics shares overreacted yesterday to news of a clinical hold on the Phase 1 trial ATTCK-20-2, which may provide an attractive entry point, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst says that although the clinical hold raises concerns on potential "narrower-than-expected therapeutic window" of ACTR-087 in B-cell malignancies, his comfort in a positive outlook of ATTCK-20-02 and ACTR-T cells in general is derived from the fact that approved CAR-T therapies, Kymriah and Yescarta, are both associated with similar serious adverse events. The analyst reiterates a Buy rain on Unum Therapeutics with an $18 price target ahead of the company's multiple data in 2019.

TODAY'S FREE FLY STORIES

JWN

Nordstrom

$26.29

1.16 (4.62%)

14:49
08/21/19
08/21
14:49
08/21/19
14:49
Options
Nordstrom options imply 18.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.44

2.41 (0.83%)

, SPX

S&P 500

$0.00

(0.00%)

14:46
08/21/19
08/21
14:46
08/21/19
14:46
General News
Fed minutes show July rate cut to help keep growth, insure against low inflation »

According to the minutes…

SPY

SPDR S&P 500 ETF Trust

$292.44

2.41 (0.83%)

SPX

S&P 500

$0.00

(0.00%)

SMH

Market Vectors Semiconductor

$114.59

1.16 (1.02%)

IWM

iShares Trust Russell 2000 Index Fund

$150.37

1.255 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXL

American Axle

$6.75

0.1 (1.50%)

14:45
08/21/19
08/21
14:45
08/21/19
14:45
Options
American Axle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$63.93

0.47 (0.74%)

14:41
08/21/19
08/21
14:41
08/21/19
14:41
Hot Stocks
Gilead says submitted petitions to USPTO requesting review of HHS patents »

Gilead announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

14:40
08/21/19
08/21
14:40
08/21/19
14:40
General news
Treasury Action: there was scant movement in the markets »

Treasury Action: there…

AEP

American Electric

$91.13

0.38 (0.42%)

14:36
08/21/19
08/21
14:36
08/21/19
14:36
Hot Stocks
American Electric seeks proposals for several coal types »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APU

AmeriGas

$31.21

-0.82 (-2.56%)

, UGI

UGI Corporation

$48.95

0.45 (0.93%)

14:32
08/21/19
08/21
14:32
08/21/19
14:32
Hot Stocks
AmeriGas unitholders approve merger with UGI Corporation »

UGI Corporation (UGI) and…

APU

AmeriGas

$31.21

-0.82 (-2.56%)

UGI

UGI Corporation

$48.95

0.45 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,192.55

9.12 (0.77%)

, GOOGL

Alphabet Class A

$1,193.00

8.74 (0.74%)

14:31
08/21/19
08/21
14:31
08/21/19
14:31
Periodicals
Google DeepMind's Suleyman placed on leave, Bloomberg reports »

Mustafa Suleyman,…

GOOG

Alphabet

$1,192.55

9.12 (0.77%)

GOOGL

Alphabet Class A

$1,193.00

8.74 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

OIH

Oil Services Holders Trust

$11.64

0.04 (0.34%)

14:30
08/21/19
08/21
14:30
08/21/19
14:30
Options
Delta neutral put sale in Oil Services ETF appears to take gains »

Delta neutral put sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMIA

Jumia Technologies

$12.54

-2.15 (-14.64%)

14:18
08/21/19
08/21
14:18
08/21/19
14:18
On The Fly
Citron target Jumia plunges as improper orders on platform put under review »

Shares of Jumia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/19
08/21
14:17
08/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FOMC minutes didn't provide strong clues on the direction of rates »

FOMC minutes didn't…

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FX Action: The dollar »

FX Action: The dollar…

WYND

Wyndham Destinations

$42.79

0.21 (0.49%)

14:11
08/21/19
08/21
14:11
08/21/19
14:11
Hot Stocks
Wyndham Destinations to add 140 jobs in Orlando expansion »

Wyndham Destinations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

, SPX

S&P 500

$0.00

(0.00%)

14:04
08/21/19
08/21
14:04
08/21/19
14:04
General news
Fed minutes show 'couple of participants' would have preferred 50 bps rate cut »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

, POAHY

Porsche

$0.00

(0.00%)

14:03
08/21/19
08/21
14:03
08/21/19
14:03
Hot Stocks
Porsche acquires minority stake in Israeli startup TriEye »

Volkswagen's (VLKAY)…

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

, SPX

S&P 500

$0.00

(0.00%)

14:02
08/21/19
08/21
14:02
08/21/19
14:02
General news
Fed minutes show July rate cut viewed by 'most' on FOMC as 'recalibration' »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.06

0.44 (1.27%)

14:01
08/21/19
08/21
14:01
08/21/19
14:01
Hot Stocks
Pfizer says FDA grants XTANDI application priority review »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

TGT

Target

$102.13

16.555 (19.35%)

13:52
08/21/19
08/21
13:52
08/21/19
13:52
Recommendations
Target analyst commentary at Baird »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

JMIA

Jumia Technologies

$12.43

-2.26 (-15.38%)

13:47
08/21/19
08/21
13:47
08/21/19
13:47
Recommendations
Jumia Technologies analyst commentary at Stifel »

Jumia's report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.